Friday, January 10, 2020
11:39 AM EST – Voyageur Pharmaceuticals Ltd : Announced the formulation and registration submission of Natural and Non Prescription Drug (NNHP) applications to Health Canada’s for one additional radiographic product named MultiXthin. MultiXthin is a specially formulated, low density, pre-mixed barium suspension product. It will be sold in a two-litre container and is for multiple testing applications. Barium sulfate suspension is for oral consumption to aid in radiographic x-ray procedures to view the upper gastrointestinal tract (esophagus, stomach, duodenum). MultiXthin is similar in composition to the dry powdered MultiXba. However, the barite has been pre-mixed in solution with 60% barium and is designed to provide ultra-fine particle distribution for superior coating of the GI Trac. Voyageur Pharmaceuticals Ltd (V.VM) shares were unchanged at 0.08.
Stocks in Play: Voyageur Pharmaceuticals Ltd, Fri, 10 Jan 2020 11:42:58 EST